CEL-SCI CORPORATION Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3
CEL-SCI CORPORATION (CVM) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3 of $0 for the 12-month period ending 2015-09-30, per its 10-K filed 2015-12-11.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3 · last filed 2015-12-11
- CEL-SCI CORPORATION fair value, measurement with unobservable inputs reconciliation, liability, transfers out of level 3 for the quarter ending 2015-09-30 was $0.00.
- CEL-SCI CORPORATION fair value, measurement with unobservable inputs reconciliation, liability, transfers out of level 3 for the quarter ending 2014-12-31 was $0.00.
- CEL-SCI CORPORATION fair value, measurement with unobservable inputs reconciliation, liability, transfers out of level 3 for the quarter ending 2014-09-30 was $0.00.
- CEL-SCI CORPORATION fair value, measurement with unobservable inputs reconciliation, liability, transfers out of level 3 for the quarter ending 2014-06-30 was $0.00.
- CEL-SCI CORPORATION fair value, measurement with unobservable inputs reconciliation, liability, transfers out of level 3 for fiscal 2015 was $0.00.
- CEL-SCI CORPORATION fair value, measurement with unobservable inputs reconciliation, liability, transfers out of level 3 for fiscal 2014 was -$7.32M.
- CEL-SCI CORPORATION fair value, measurement with unobservable inputs reconciliation, liability, transfers out of level 3 for fiscal 2013 was $0.00.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3 12 month |
|---|---|---|---|---|
| 2015-09-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-12-11 | $0.00 10-K · filed 2015-12-11 | ||
| 2015-06-30 | $0.00 10-Q · filed 2015-08-07 | |||
| 2014-12-31 | $0.00 10-Q · filed 2015-02-06 | $0.00 derived: sum of 2 quarters · filed 2015-12-11 | $0.00 derived: sum of 3 quarters · filed 2015-12-11 | |
| 2014-09-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-12-11 | $0.00 derived: sum of 2 quarters · filed 2015-12-11 | -$7.32M 10-K · filed 2015-12-11 | |
| 2014-06-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-08-08 | -$7.32M 10-Q · filed 2014-08-08 | ||
| 2014-03-31 | -$7.32M 10-Q · filed 2014-05-12 | |||
| 2013-09-30 | $0.00 10-K · filed 2014-12-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |